Monopar Therapeutics (MNPR) announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor, with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor growth and metastasis, and is found in some of the most aggressive, deadly cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics price target raised to $37 from $9 at JonesResearch
- Monopar Therapeutics price target raised to $22 from $6 at H.C. Wainwright
- Monopar Therapeutics reports Q3 EPS (37c), consensus (48c)
- Monopar Therapeutics Closes $19.2 Million Stock Offering
- Monopar Therapeutics 1.16M share Spot Secondary priced at $16.25